{"doi":"10.1093/cid/ciab968","title":"Infectious Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Virus in Symptomatic Coronavirus Disease 2019 (COVID-19) Outpatients: Host, Disease, and Viral Correlates","abstract":"BACKGROUND: Although severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectious virus isolation in outpatients with coronavirus disease 2019 (COVID-19) has been associated with viral RNA levels and symptom duration, little is known about the host, disease, and viral determinants of infectious virus detection. METHODS: COVID-19 adult outpatients were enrolled within 7 days of symptom onset. Clinical symptoms were recorded via patient diary. Nasopharyngeal swabs were collected to quantitate SARS-CoV-2 RNA by reverse transcriptase polymerase chain reaction and for infectious virus isolation in Vero E6-cells. SARS-CoV-2 antibodies were measured in serum using a validated ELISA assay. RESULTS: Among 204 participants with mild-to-moderate symptomatic COVID-19, the median nasopharyngeal viral RNA was 6.5 (interquartile range [IQR] 4.7-7.6 log10 copies/mL), and 26% had detectable SARS-CoV-2 antibodies (immunoglobulin (Ig)A, IgM, IgG, and/or total Ig) at baseline. Infectious virus was recovered in 7% of participants with SARS-CoV-2 antibodies compared to 58% of participants without antibodies (prevalence ratio [PR] = 0.12, 95% confidence interval [CI]: .04, .36; P = .00016). Infectious virus isolation was also associated with higher levels of viral RNA (mean RNA difference +2.6 log10, 95% CI: 2.2, 3.0; P < .0001) and fewer days since symptom onset (PR = 0.79, 95% CI: .71, .88 per day; P < .0001). CONCLUSIONS: The presence of SARS-CoV-2 antibodies is strongly associated with clearance of infectious virus. Seropositivity and viral RNA levels are likely more reliable markers of infectious virus clearance than subjective measure of COVID-19 symptom duration. Virus-targeted treatment and prevention strategies should be administered as early as possible and ideally before seroconversion. CLINICAL TRIALS REGISTRATION: NCT04405570.","journal":"Clinical Infectious Diseases","year":2021,"id":200737,"datarank":0.5466635936219892,"base_score":2.1972245773362196,"endowment":2.1972245773362196,"self_citation_contribution":0.32958368660043297,"citation_network_contribution":0.2170799070215563,"self_endowment_contribution":0.32958368660043297,"citer_contribution":0.2170799070215563,"corpus_percentile":null,"corpus_rank":null,"citation_count":8,"citer_count":6,"citers_with_citation_signal":5,"citers_with_endowment":5,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.956,"is_data_producer":true,"deposit_databanks":{"ClinicalTrials.gov":["NCT04405570"]},"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2021-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":249713,"name":"Joseph J. Eron","orcid":"0000-0002-4938-0644","position":1,"is_corresponding":false},{"id":778548,"name":"Taylor Krajewski","orcid":"0000-0001-7410-8370","position":2,"is_corresponding":false},{"id":778549,"name":"Wendy Painter","orcid":"0000-0001-6710-1277","position":3,"is_corresponding":false},{"id":326527,"name":"Elizabeth R. Duke","orcid":"0000-0002-3348-9039","position":4,"is_corresponding":false},{"id":503541,"name":"Caryn G. Morse","orcid":"0000-0002-1177-4365","position":5,"is_corresponding":false},{"id":593768,"name":"Erin A. Goecker","orcid":null,"position":6,"is_corresponding":false},{"id":103773,"name":"Lakshmanane Premkumar","orcid":"0000-0002-1736-1350","position":7,"is_corresponding":false},{"id":104963,"name":"Cameron R. Wolfe","orcid":"0000-0002-5365-5030","position":8,"is_corresponding":false},{"id":779004,"name":"Laura J. Szewczyk","orcid":null,"position":9,"is_corresponding":false},{"id":779005,"name":"Paul Alabanza","orcid":null,"position":10,"is_corresponding":false},{"id":377684,"name":"Amy James Loftis","orcid":null,"position":11,"is_corresponding":false},{"id":306822,"name":"Emily Degli-Angeli","orcid":"0000-0002-5644-5258","position":12,"is_corresponding":false},{"id":105114,"name":"Ariane J. Brown","orcid":null,"position":13,"is_corresponding":false},{"id":261330,"name":"Joan Dragavon","orcid":null,"position":14,"is_corresponding":false},{"id":105113,"name":"John J. Won","orcid":"0000-0002-5849-4993","position":15,"is_corresponding":false},{"id":597301,"name":"Jessica Keys","orcid":"0000-0001-5093-378X","position":16,"is_corresponding":false},{"id":130929,"name":"Michael G. Hudgens","orcid":"0000-0002-9106-4194","position":17,"is_corresponding":false},{"id":778550,"name":"Lei Fang","orcid":"0000-0002-2647-914X","position":18,"is_corresponding":false},{"id":340150,"name":"David A. Wohl","orcid":"0000-0002-7764-0212","position":19,"is_corresponding":false},{"id":249712,"name":"Myron S. Cohen","orcid":"0000-0001-5917-9664","position":20,"is_corresponding":false},{"id":5952,"name":"Ralph S. Baric","orcid":"0000-0001-6827-8701","position":21,"is_corresponding":false},{"id":65748,"name":"Robert W. Coombs","orcid":"0000-0003-2709-0512","position":22,"is_corresponding":false},{"id":5953,"name":"Timothy P. Sheahan","orcid":"0000-0001-9181-2183","position":23,"is_corresponding":false},{"id":109932,"name":"William A. Fischer","orcid":"0000-0002-4900-098X","position":24,"is_corresponding":false},{"id":334763,"name":"Katie R. Mollan","orcid":"0000-0002-8592-5154","position":0,"is_corresponding":true}],"reference_count":29,"raw_metadata":null,"created_at":"2026-07-18T23:50:48.624274Z","pmid":"35022711","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}